Savior Lifetec (4167) - Total Liabilities

Latest as of December 2025: NT$403.30 Million TWD ≈ $12.71 Million USD

Based on the latest financial reports, Savior Lifetec (4167) has total liabilities worth NT$403.30 Million TWD (≈ $12.71 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Savior Lifetec (4167) cash flow conversion to assess how effectively this company generates cash.

Savior Lifetec - Total Liabilities Trend (2011–2025)

This chart illustrates how Savior Lifetec's total liabilities have evolved over time, based on quarterly financial data. Check 4167 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Savior Lifetec Competitors by Total Liabilities

The table below lists competitors of Savior Lifetec ranked by their total liabilities.

Company Country Total Liabilities
BayWa AG vNa
XETRA:BYW6
Germany €9.76 Billion
Midnight Sun Mining Corp
V:MMA
Canada CA$691.56K
Lucky Cement Co
TW:1108
Taiwan NT$4.41 Billion
New Power Plasma Co.Ltd
KQ:144960
Korea ₩567.46 Billion
Barings Participation Investors (the Trust)
NYSE:MPV
USA $25.42 Million
Bossa Ticaret ve Sanayi Isletmeleri TAS
IS:BOSSA
Turkey TL4.23 Billion
Dynamix Corporation Class A Ordinary Shares
NASDAQ:DYNX
USA $11.14 Million
Tonix Pharmaceuticals Holding Corp
NASDAQ:TNXP
USA $32.02 Million

Liability Composition Analysis (2011–2025)

This chart breaks down Savior Lifetec's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 4167 market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 11.06 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.11 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.10 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Savior Lifetec's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Savior Lifetec (2011–2025)

The table below shows the annual total liabilities of Savior Lifetec from 2011 to 2025.

Year Total Liabilities Change
2025-12-31 NT$403.30 Million
≈ $12.71 Million
-53.11%
2024-12-31 NT$860.02 Million
≈ $27.10 Million
+87.80%
2023-12-31 NT$457.96 Million
≈ $14.43 Million
-56.04%
2022-12-31 NT$1.04 Billion
≈ $32.82 Million
-15.01%
2021-12-31 NT$1.23 Billion
≈ $38.62 Million
-18.63%
2020-12-31 NT$1.51 Billion
≈ $47.46 Million
-17.20%
2019-12-31 NT$1.82 Billion
≈ $57.32 Million
+8.71%
2018-12-31 NT$1.67 Billion
≈ $52.73 Million
-6.21%
2017-12-31 NT$1.78 Billion
≈ $56.22 Million
+35.46%
2016-12-31 NT$1.32 Billion
≈ $41.51 Million
-20.32%
2015-12-31 NT$1.65 Billion
≈ $52.09 Million
-10.10%
2014-12-31 NT$1.84 Billion
≈ $57.94 Million
+34.23%
2013-12-31 NT$1.37 Billion
≈ $43.16 Million
+24.18%
2012-12-31 NT$1.10 Billion
≈ $34.76 Million
+8.16%
2011-12-31 NT$1.02 Billion
≈ $32.14 Million
--

About Savior Lifetec

TWO:4167 Taiwan Biotechnology
Market Cap
$185.34 Million
NT$5.88 Billion TWD
Market Cap Rank
#16823 Global
#831 in Taiwan
Share Price
NT$18.95
Change (1 day)
-0.79%
52-Week Range
NT$17.00 - NT$22.00
All Time High
NT$40.63
About

Savior Lifetec Corporation, a specialty injectable company, develops, produces, and supplies sterile active pharmaceutical ingredients and finished dosage formulations. The company provides various carbapenem generic drugs and injections, such as paliperidone palmitate, cetrorelix and ganirelix acetate, plecanatide, prucalopride succinate, and brinzolamide. It offers imipenem and cilastatin, mero… Read more